Sophisticated blood analysis provides new clues about Ebola, treatment avenues

A detailed analysis of blood samples from Ebola patients in Sierra Leone is providing clues about the progression of the effects of the Ebola virus in patients and potential treatment pathways. The findings point to a critical role for a molecular pathway that relies on the common nutrient choline, as well as the importance of cellular bodies known as microvesicles.

Laboratory management of Crimean-Congo hemorrhagic fever virus infections: perspectives from two European networks

Researchers amalgamated the expertise of two European Union expert networks:  EMERGE (Efficient response to highly dangerous and emerging pathogens at EU level) and EVD-LabNet (Emerging Viral Diseases Laboratory Network), in order to select and analyze the relevant and some of controversial aspects of Crimean-Congo hemorrhagic fever (CCHF) disease diagnostics with implications for laboratory management of human CCHF cases and any exposed contacts.

Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo

Researchers showed that sofosbuvir, clinically approved against hepatitis C, inhibits yellow fever virus replication in liver cell lines and animal models. In vitro, sofosbuvir inhibits viral RNA replication, decreases the number of infected cells and the production of infectious virus particles.

Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza

These clinical practice guidelines are an update of the guidelines published by the Infectious Diseases Society of America (IDSA) in 2009, prior to the 2009 H1N1 influenza pandemic. This document addresses new information regarding diagnostic testing, treatment and chemoprophylaxis with antiviral medications, and issues related to institutional outbreak management for seasonal influenza.

Synthetic DNA-delivered Antibodies Protect Against Ebola in Preclinical Studies Representing a Novel Platform for Antibody Therapies for Outbreak Infections

Scientists have successfully engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that were effective in preclinical models. DMAbs may also provide a novel powerful platform for rapid screening of monoclonal antibodies enhancing preclinical development.